The First Affiliated Hospital Of Soochow University

This study tests a new combination of three drugs (venetoclax, azacitidine, and mitoxantrone liposome) against the standard two-drug therapy for adults newly diagnosed with acute myeloid leukemia (AML). About 204 participants aged 18 to 65 will be randomly assigned to receive eit…

This study tests a new treatment plan for young adults and adults with B-cell acute lymphoblastic leukemia (B-ALL). The plan combines immunotherapy before a stem cell transplant using the patient's own cells, followed by a 'sandwich' of two types of CAR-T cells (CD22 and CD19). T…

This study tests a new combination of drugs (glofitamab plus chemotherapy) for people with large B-cell lymphoma that has come back or not responded to first treatment. About 96 adults will be randomly assigned to get either the new combo or standard care. The goal is to see if t…

This study tests a new drug called iparomlimab/tuvonralimab (QL1706) combined with standard chemotherapy followed by olaparib in women with platinum-sensitive recurrent ovarian cancer. The goal is to see if this combination can help control the cancer and delay its return. About …

This study tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can lower the chance of leukemia coming back. It includes 160 people aged 15-60 with high-risk or relapsed acute leukemia or myelodysplastic syndromes. Parti…

This study tests whether a combination of two drugs (venetoclax and azacitidine) works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults with high-risk AML who are already in remission…

This study tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can help people with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndromes (MDS). About 180 participants aged 15-60 will be randomly a…

This study tests a combination of two drugs (Bcl-2 inhibitor and azacitidine) in people newly diagnosed with a rare, aggressive leukemia called mixed phenotype acute leukemia (MPAL). The goal is to see if this treatment can put the cancer into remission and allow patients to rece…